MA42017B1 - Anti-cd154 antibody with improved binding, functionality and safety characteristics and its use in human immunotherapy - Google Patents
Anti-cd154 antibody with improved binding, functionality and safety characteristics and its use in human immunotherapyInfo
- Publication number
- MA42017B1 MA42017B1 MA42017A MA42017A MA42017B1 MA 42017 B1 MA42017 B1 MA 42017B1 MA 42017 A MA42017 A MA 42017A MA 42017 A MA42017 A MA 42017A MA 42017 B1 MA42017 B1 MA 42017B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- functionality
- improved binding
- safety characteristics
- binding
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000002679 ablation Methods 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps anti-cd154 qui présentent des propriétés améliorées en termes de pouvoir thérapeutique, demi-vie in vivo et liaison à un fcr d'ablation et/ou liaison/activation d'un complément. L'invention concerne également l'utilisation de ces anticorps pour l'induction de la tolérance et le traitement de maladies immunitaires, comprenant l'auto-immunité, l'inflammation, les personnes transplantées, la fibrose et les troubles allergiques.The present invention relates to anti-cd154 antibodies which exhibit improved properties in terms of therapeutic potency, half-life in vivo and binding to ablation rf and / or binding / activation of complement. The invention also relates to the use of these antibodies for the induction of tolerance and the treatment of immune diseases, including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42017B1 true MA42017B1 (en) | 2020-11-30 |
Family
ID=73643391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42017A MA42017B1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody with improved binding, functionality and safety characteristics and its use in human immunotherapy |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA42017B1 (en) |
-
2016
- 2016-07-13 MA MA42017A patent/MA42017B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500098A1 (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| MX2012007318A (en) | Tetravalent cd47-antibody constant region fusion protein for use in therapy. | |
| ZA202006481B (en) | Anti-msr1 antibodies and methods of use thereof | |
| MX2025008493A (en) | Fibroblast binding agents and use thereof | |
| CR20210239A (en) | IL-15/IL-15RALFA-FC FUSION PROTEINS TARGETING PD-1 AND USES THEREOF IN COMBINATION THERAPIES | |
| WO2019028306A3 (en) | Compositions and methods for delivery of aav | |
| MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| MA47313A (en) | SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES | |
| MY202870A (en) | Anti-ctla-4 antibodies and uses thereof | |
| WO2011139357A8 (en) | Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases | |
| MA35437B1 (en) | Fusion Proteins for the Treatment of Metabolic Disorders | |
| EA200601575A1 (en) | CASEIN PEPTIDES AND THEIR THERAPEUTIC APPLICATION | |
| WO2015031673A3 (en) | Cns-targetedconjugates of antibodies | |
| MY204068A (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| MA40754B1 (en) | Compositions comprising bacterial strains | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| UA112743C2 (en) | THERAPEUTIC DLL4 Binding Protein | |
| AU2015255979B2 (en) | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses | |
| MA43113A (en) | ANTI-HTR A1 ANTIBODIES AND METHODS OF USING THEM | |
| MA40224A (en) | ANTIBODIES BINDING TO ENHANCED ASS PROTOFIBRILLES | |
| JO3462B1 (en) | Human Antibodies to GFR?3 and methods of use thereof | |
| MA39342B2 (en) | Il -21 antibody | |
| WO2012138768A3 (en) | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies | |
| PH12020551805A1 (en) | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof | |
| MY205028A (en) | Protein for treatment of inflammatory diseases |